Application for Regulatory Approvals, Conferences and Presentations, and Enrollment in Clinical Trials - Research Report on

   Application for Regulatory Approvals, Conferences and Presentations, and
 Enrollment in Clinical Trials - Research Report on Gilead, Alnylam, Omeros,
                              PTC, and Stemline

PR Newswire

NEW YORK, September 26, 2013

NEW YORK, September 26, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Gilead
Sciences Inc. (NASDAQ: GILD), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY),
Omeros Corporation (NASDAQ: OMER), PTC Therapeutics, Inc. (NASDAQ: PTCT), and
Stemline Therapeutics, Inc. (NASDAQ: STML). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Gilead Sciences Inc. Research Report

On September 11, 2013, Gilead Sciences Inc. (Gilead) announced its submission
of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)
for approval of idelalisib for the treatment of indolent non-Hodgkin's
lymphoma (iNHL). According to Gilead, the data submitted for the NDA support
the use of idelalisib for patients with iNHL that is refractory
(non-responsive) to rituximab and to alkylating-agent-containing chemotherapy.
John C. Martin, PhD, Chairman and CEO of Gilead Sciences, stated, "Based on
the rate and duration of response observed to date in this highly refractory
iNHL patient population, we believe idelalisib could become an important new
therapy for patients who have limited treatment options." According to Gilead,
Idelalisib is an investigational, targeted, highly selective oral inhibitor of
phosphoinositide 3-kinase (PI3K) delta: a protein that is critical for the
activation, proliferation and survival of B lymphocytes. The Full Research
Report on Gilead Sciences Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-09-23/GILD]

--

Alnylam Pharmaceuticals, Inc. Research Report

On September 20, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced that
its management will give an overview of the Company during the upcoming 20th
Annual NewsMakers in the Biotech Industry Conference. Alnylam reported that
the presentation will be held at 2:30 p.m. ET, on September 27, 2013 at the
Millennium Broadway Hotel in New York City. The Company also stated that a
live audio webcast will be available on the News & Investors section of its
website. Further, the archive of the presentation will also be available on
its website within 48 hours after the conclusion of the event. The Full
Research Report on Alnylam Pharmaceuticals, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.InvestorsReports.com/report/2013-09-23/ALNY]

--

Omeros Corporation Research Report

On September 19, 2013, Omeros Corporation (Omeros) announced the initiation
of enrollment in a Phase 2 clinical trial of OMS824, the Company's
phosphodiesterase 10 (PDE10) inhibitor. Gilead reported that the trial will
evaluate the compound's tolerability, safety, pharmacokinetics, potential
interactions with concomitant antipsychotic medications, and a battery of
cognitive tests in patients with stable schizophrenia. According to Omeros,
PDE10 is an enzyme that is expressed in areas of the brain linked to diseases
that affect cognition and psychomotor functions, including Huntington's
disease and schizophrenia. The Company stated that in this Phase 2 clinical
trial, OMS824 will be administered at various dose levels for two weeks to
patients whose antipsychotic medications have been temporarily discontinued or
who continue their usual antipsychotic regimen in order to assess the effects
of OMS824 as monotherapy and in combination with antipsychotic medications.
Gregory A. Demopulos, M.D., Chairman and CEO of Omeros, said, "This Phase 2
trial will provide us with important information on our compound's safety and,
potentially, efficacy for additional Phase 2 trials in schizophrenia and
Huntington's disease. We look forward to completing the current trial later
this year." The Full Research Report on Omeros Corporation - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.InvestorsReports.com/report/2013-09-23/OMER

PTC Therapeutics, Inc. Research Report

On September 18, 2013, PTC Therapeutics, Inc. (PTC) announced that two of its
abstracts have been accepted for the 10th European Pediatric Neurology Society
Congress (EPNS) in Brussels, Belgium, to be held from September 25, 2013 to
September 28, 2013. According to the Company, the two abstracts are: Design of
a confirmatory phase 3, multicenter, randomized, double-blind,
placebo-controlled study of ataluren in patients with nonsense mutation
Duchenne muscular dystrophy; and Disease-related symptoms and activities of
daily living: a novel survey of patients with nonsense mutation Duchenne
muscular dystrophy, which will be presented on September 25, 2013 at 13:30
p.m. PTC also informed that it will sponsor a symposium at EPNS titled New
perspectives in the management of Duchenne muscular dystrophy on September 25,
2013 from 12:30 p.m. to 13:30 p.m. The Full Research Report on PTC
Therapeutics, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-09-23/PTCT]

--

StemlineTherapeutics, Inc. Research Report

On September 19, 2013, Stemline Therapeutics, Inc. (Stemline) announced that
the Company will be participating at the Aegis Capital Corporation 2013
Healthcare Conference to be held at the Encore at Wynn Las Vegas from
September 26, 2013 to September 28, 2013. Stemline informed that Ivan
Bergstein, M.D., CEO of the Company, will give a presentation at the event on
September 28, 2013 at 9:45 a.m. PDT. The Full Research Report on Stemline
Therapeutics, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-09-23/STML]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Investors' Reports

Contact: CONTACT PERSON: Kristi Saunders CONTACT PHONE: +1-315-982-6420 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.